Market Place
Sourcing Support
Lynk Pharma Reports Positive Phase 1b Results For LNK01004 In Dermatitis
13 Aug 2024 //
PR NEWSWIRE
Lynk Announced First Rheumatoid Arthritis Patient Dosed in PIII of LNK01001
20 Dec 2023 //
PR NEWSWIRE
Lynk Pharmaceuticals Completes Series C2 Financing Round
21 Sep 2023 //
PR NEWSWIRE
Lynk hits main goal to wrap up clean sweep of phase 2 JAK trials
23 Aug 2023 //
FIERCE BIOTECH
Lynk Announced Positive Topline Data from Phase II Clinical Trial of LNK01001
09 Aug 2023 //
PR NEWSWIRE
Lynk’s JAK1 inhibitor improves severity, itching in eczema study
09 Aug 2023 //
FIERCE BIOTECH
Lynk Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Ph Ib
21 Jul 2023 //
PR NEWSWIRE
Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing
31 May 2023 //
PR NEWSWIRE
Lynk doses first cohort in Phase Ib trial of psoriasis therapy
25 May 2023 //
CLINICAL TRIALS ARENA
Lynk Announces First Cohort of Psoriatic Patients Dosed with LNK01004
25 May 2023 //
PR NEWSWIRE
Lynk Announces Positive Results for LNK01003 in PI Trial in Healthy Subjects
04 Apr 2023 //
PR NEWSWIRE
Lynk Announces First Patient Dosed in Phase ? Clinical Study of LNK01003
05 Dec 2022 //
PRNEWSWIRE
Lynk Pharmaceuticals` IND Approved for LNK01004 in Atopic Dermatitis in China
03 Aug 2022 //
PRNEWSWIRE
Lynk doses first subject in Phase I trial of plaque psoriasis drug
01 Aug 2022 //
CLINICALTRIALSARENA
Lynk Pharma Begins Dosing in Phase I Trial of LNK01004
29 Jul 2022 //
PRNEWSWIRE
Lynk Pharmaceuticals gets clinical approval in China for Class I LNK01004
22 Apr 2022 //
BIOSPECTRUMASIA
Lynk Pharma, Simcere enter Strategic Commercialization Partnership for LNK01001
18 Mar 2022 //
PRNEWSWIRE
Lynk Pharma Announces 1st Patient Dosed in Phase II Clinical Study of LNK01001
28 Feb 2022 //
PRNEWSWIRE
Lynk Pharma Begins Dosing in Phase II of LNK01001 in Ankylosing Spondylitis
19 Jan 2022 //
PRNEWSWIRE
Lynk Pharma begins dosing in phase II study of LNK01001 for rheumatoid arthritis
06 Dec 2021 //
PHARMABIZ
Lynk Announced First Patient Dosed in Phase II Clinical Study of LNK01001
01 Dec 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.